Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Golcadomide · CC-99282, CC1007548

Small molecule (Molecular glue degrader) · Degrader of cereblon (CRBN) · developed by Celgene

Phase 1/2 Most advanced trial
BMY Developer
1 Registered trials

What is Golcadomide?

Golcadomide is a small molecule that modulates the CRL4-CRBN E3 ubiquitin ligase by binding cereblon. This directs ubiquitination and proteasome-mediated degradation of certain transcription factors, activating T-lymphocytes. It is being studied in peripheral T-cell lymphoma and follicular helper T-cell lymphoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
CC-99282, CC1007548
Drug type
Small molecule (Molecular glue degrader)
Targets
cereblon (CRBN)
Mechanism
Degrader of cereblon (CRBN)
Pathways
CRL4-CRBN E3 ubiquitin ligase-mediated ubiquitination, proteasome-mediated degradation of transcription factors, T-lymphocyte activation
Therapy area
Oncology
Developer
Celgene (BMY)
Also in trials of
ABBV
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
29HLR8Z5BR

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07018752 Phase 1/2 Peripheral T Cells Lymphoma (PTCL) Recruiting ABBV

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Follicular Helper T-Cell LymphomaPeripheral T Cells Lymphoma (PTCL)

Other drugs acting on CRBN

More from Celgene

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the BMY page.

Follow BMY, the company behind Golcadomide

See BMY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BMY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.